Onyx
Pharmaceuticals, Inc. ONXX today announced that it will
hold a conference call to discuss data presented at an ASCO plenary
session from the DECISION study, a Phase 3 trial investigating the
use of Nexavar(R) (sorafenib) tablets in patients with locally
advanced or metastatic radioactive iodine-refractory (RAI)
differentiated thyroid cancer. The call will feature the principal
investigator, Marcia Brose, M.D., Ph.D., Assistant Professor in the
Abramson Cancer Center and the Perelman School of Medicine at the
University of Pennsylvania, and will include members of Onyx's
management.
Date: Monday, June 3, 2013
Time: 10:15 - 11:00 a.m. Central Time
To access a live audio webcast of the conference call, log onto the
company's website at: http://www.onyx.com/investors/event-calendar
To access the live conference call, dial 847-585-4405 and use the
passcode 34979134 #. A replay of the call will be available on the
Onyx website or by dialing 630-652-3042 and using the passcode
34979134 # approximately one hour after the conference call concludes
through June 17, 2013.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in